Corcept Therapeutics Inc CORT
Corcept Therapeutics Inc (Nasdaq: CORT) is an oncology drug developer. Its lead program, Lifyorli (relacorilant) + nab-paclitaxel, is in Phase 3 for Platinum-resistant ovarian cancer. Its next catalyst on record is Relacorilant for hypercortisolism: FDA PDUFA decision (December 2026).
Upcoming catalysts
- December 2026Relacorilant for hypercortisolism — FDA PDUFA decision
The Prescription Drug User Fee Act target date for the FDA to complete its review is December 17, 2026.
Next further out: Relacorilant for platinum-resistant ovarian cancer — EC approval decision (Q4 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Korlym (mifepristone) | Hypercortisolism (Cushing's syndrome) | small molecule | Approved |
| Lifyorli (relacorilant) + nab-paclitaxel | Platinum-resistant ovarian cancer | small molecule | Approved |
| Relacorilant | Endogenous hypercortisolism | small molecule | Phase 3 |
| Lifyorli + nab-paclitaxel + bevacizumab (BELLA Part A) | Platinum-resistant ovarian cancer | small molecule | Phase 2 |
| Lifyorli + nab-paclitaxel + bevacizumab (BELLA Part B) | Platinum-sensitive ovarian cancer (post-PARP inhibitor) | small molecule | Phase 2 |
| Lifyorli + nab-paclitaxel (BELLA Part C) | Endometrial cancer | small molecule | Phase 2 |
| Lifyorli + nab-paclitaxel + gemcitabine (TRIDENT) | Pancreatic cancer | small molecule | Phase 2 |
| Lifyorli + nab-paclitaxel (STELLA) | Cervical cancer | small molecule | Phase 2 |
| Relacorilant + enzalutamide | Prostate cancer (pre-prostatectomy) | small molecule | Phase 2 |
| Miricorilant (MONARCH) | MASH (metabolic dysfunction-associated steatohepatitis) | small molecule | Phase 2 |
| Dazucorilant (DAZALS) | Amyotrophic lateral sclerosis (ALS) | small molecule | Phase 2 |
| Nenocorilant + nivolumab (SYNERGY) | Solid tumors | small molecule | Phase 1 |
Recent results and decisions
- Nov 3, 2026positive BELLA Part A Phase 2 trial of relacorilant plus nab-paclitaxel and bevacizumab in platinum-resistant ovarian cancer demonstrated clinically meaningful progression-free survival, objective response rate, and overall survival.
BELLA Part A –Phase 2 trial of relacorilant plus nab-paclitaxel and bevacizumab in 95 patients with platinum-resistant ovarian cancer demonstrated clinically meaningful median PFS of 7.2 months, ORR of 59 percent and OS of 88 percent at 6-months.
Filing - Nov 3, 2026started STELLA Phase 2 trial of relacorilant plus nab-paclitaxel in cervical cancer initiated.
STELLA – Initiated Phase 2 trial of relacorilant plus nab-paclitaxel in 50 patients with cervical cancer (received one or two prior lines of therapy), conducted in collaboration with ARCAGY-GINECO
Filing - Jul 29, 2026accepted Resubmitted relacorilant NDA in Cushing's syndrome carries a PDUFA date of December 17, 2026.
New Drug Application for relacorilant resubmitted with a Prescription Drug User Fee Act (PDUFA) date of December 17, 2026
Filing
6 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Astrazeneca PLC AZN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Guardant Health, Inc. GH
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.